Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive treatment, Seres Therapeutics is pausing that investment and sending more employees to the exits.
- Home |
- Seres to lay off 30% of employees, pause lead program in latest strategic shift
Seres to lay off 30% of employees, pause lead program in latest strategic shift
- February 12, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
